Gains de lARNM ; Explorer le potentiel futur
Moderna has become famous for its COVID-19 vaccine, which is the only product it has right now. However, the company has plans to launch more than 15 products in the next five years. These products could change the game for the company, as they could make the annual revenue go up to $30 Billion. The Moderna stock shot up on the back of Modernas Covid-19 vaccine.Moderna is planning to launch 15 new products over the next 5 years, and expects revenue to go up to $30 Billion. The new products will be for diseases, cancer, breathing problems among other ailments. Moderna Earnings Results Moderna (NASDAQ: MRNA) reported revenue of $1.83 Billion showcasing a year-over-year decline of 45.6% and EPS of -$1.39 for the span of time compared to $2.53 a year ago. When the revenue compares to the Zacks Consensus Estimate of $1.33 Billion it showcases a surprise of 37.59% and it also gave an EPS surprise of 30.85% with the consensus EPS estimate of -$2.01. Furthermore, the company reported a Net income of -3.63 Billion with a negative profit margin of -198.25%. Que se passe-t-il sur les fiches techniques ? Moderna price action indicates bullishness, as MRNA stock took a reversal and headed towards the